tirzepatide and hormones FDA approval for Zepbound (tirzepatide) injection, the first only obesity treatment of its kind that activates both GIP and GLP-1 hormone receptors - Eli Lilly Mounjaro Tirzepatide Injection for Type

Medication Mechanism of Action Average Weight Loss Retatrutide Triple agonist (GLP-1, GIP, Glucagon) Up to 24% average weight loss over 48 weeks Semaglutide GLP-1 receptor agonist Up to 17% over 68 weeks Tirzepatide Dual agonist (GLP-1, GIP) Up to 25% over 52 weeks Retatrutide is used to help with weight loss

Individuals need to weigh risks and benefits

Those who have a history of urinary tract infections may want to avoid Ozempic, Smith said

However, you should contact your GP or diabetes care team if symptoms are recurrent, severe, or significantly impact daily activities, as dose adjustment or medication review may be necessary